MD
Mary DiBiase
Chief Operating Officer

Mary DiBiase insider trades: X4 Pharmaceuticals (XFOR) stock sales

Chief Operating Officer, X4 Pharmaceuticals Last trade Jan 24, 2025 23 Form 4 filings
$0
Sold, last 12 months
0 sales
$0
Bought, last 12 months
0 buys
12
Open-market trades
since 2023
1
Company
last trade 2025

Trades on the price chart

Daily close, with an arrow on each day they bought or sold

Companies

Where Mary reports to the SEC

Open-market buys and sales

12 trades reported on SEC Form 4, newest first

DateStockTypeValue
Jan 24, 2025XFOR↓ Sell10b5-1$10K
Oct 7, 2024XFOR↓ Sell10b5-1$38K
Sep 9, 2024XFOR↓ Sell$2K
Mar 11, 2024XFOR↓ Sell$14K
Feb 12, 2024XFOR↓ Sell$4K
Nov 1, 2023XFOR↓ Sell$49K
Sep 8, 2023XFOR↓ Sell$3K
Jun 30, 2023XFOR↓ Sell$877
Jun 23, 2023XFOR↓ Sell10b5-1$2K
Jun 15, 2023XFOR↓ Sell$2K
Mar 10, 2023XFOR↓ Sell$15K
Feb 13, 2023XFOR↓ Sell$4K

Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.

Other XFOR insiders

Open-market trades in the last 12 months

About Mary DiBiase's insider trades

Mary DiBiase is Chief Operating Officer at X4 Pharmaceuticals (XFOR). Since Feb 13, 2023, Mary has reported no open-market purchases and 12 sales worth $144K on SEC Form 4. There have been no open-market trades in the last 12 months.

3 sales (35% of the value sold) were made under a Rule 10b5-1 trading plan, which is set up months in advance and runs on a schedule, so they say little about how the insider sees the stock today.

Their filings also include grants and awards (8 filings). These aren't open-market trades and aren't counted above.

How to read insider trades

Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every XFOR insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.